DUBLIN, Sept. 14, 2021 /PRNewswire/ -- The "Induced Pluripotent Stem Cell (iPSC) Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
This report provides the strategists, marketers and senior management with the critical information they need to assess the global induced pluripotent stem cell (iPSC) market as it emerges from the COVID-19 shut-down.
This report describes and explains the induced pluripotent stem cell (iPSC) market and covers 2015 to 2020, termed the historic period, and 2020 to 2025 termed the forecast period, along with further forecasts for the period 2025-2030. The report evaluates the market across each region and for the major economies within each region.
The global induced pluripotent stem cell (iPSC) market reached a value of nearly $2,223.5 million in 2020, having increased at a compound annual growth rate (CAGR) of 9.2% since 2015. The market is expected to grow from $2,223.5 million in 2020 to $3,362.1 million in 2025 at a rate of 8.6%. The market is then expected to grow at a CAGR of 6.2% from 2025 and reach $4,547.7 million in 2030.
Growth in the historic period resulted from increased healthcare spending, rise in funding, aid as non - animal alternatives for preclinical trials and increasing demand of personalized medicines. Factor that negatively affected growth in the historic period was lack of awareness on induced pluripotent stem cell.
Going forward, increasing prevalence of chronic diseases, growth genomic projects, development in iPSC models, increasing funding and increasing prevalence of genetic diseases. Factors that could hinder the growth of the induced pluripotent stem cell (iPSC) market in the future include risk associated with it and high costs associated with storage.
The induced pluripotent stem cell (iPSC) market is segmented by application into drug discovery and toxicity studies, academic research, cell & gene therapy, and regenerative medicine. The drug discovery and toxicity studies was the largest segment of the induced pluripotent stem cell (iPSC) market segmented by application, accounting for 48.7% of the total in 2020. Going forward, cell & gene therapy segment is expected to be the fastest growing segment in the induced pluripotent stem cell (iPSC) market segmented by application, at a CAGR of 9.82% during 2020-2025.
The induced pluripotent stem cell (iPSC) market is also segmented by end-user into hospitals and research laboratories. The research laboratories was the largest segment of the induced pluripotent stem cell (iPSC) market segmented by end-user, accounting for 68.5% of the total in 2020. Going forward, the hospitals segment is expected to be the fastest growing segment in the induced pluripotent stem cell (iPSC) market segmented by end-user, at a CAGR of 9.3% during 2020-2025.
The induced pluripotent stem cell (iPSC) market is also segmented by derived cell type into amniotic, hepatocytes, fibroblasts, keratinocytes and others. The fibroblasts was the largest segment of the induced pluripotent stem cell (iPSC) market segmented by derived cell type, accounting for 33.0% of the total in 2020. Going forward, the others segment is expected to be the fastest growing segment in the induced pluripotent stem cell (iPSC) market segmented by derived cell type, at a CAGR of 10.0% during 2020-2025.
The induced pluripotent stem cell (iPSC) market is fragmented, with a large number of players constituting the market. The top ten competitors in the market made up to 26% of the total market in 2020. Major players in the market include Fujifilm Holding Corporation, Thermo Fisher Scientific Inc Takara Bio Inc., ViaCyte, and Fate Therapeutics.
The top opportunities in the induced pluripotent stem cell (iPSC) market segmented by derived cell type will arise in the fibroblasts segment, which will gain $360.1 million of global annual sales by 2025. The top opportunities in the induced pluripotent stem cell (iPSC) market segmented by end-user industry will arise in the hospitals segment, which will gain $393.0 million of global annual sales by 2025. The top opportunities in the induced pluripotent stem cell (iPSC) market segmented by application will arise in the drug discovery and toxicity studies segment, which will gain $520.3 million of global annual sales by 2025. The induced pluripotent stem cell (iPSC) market size will gain the most in the USA at $132.6 million.
Key Topics Covered:
1. Induced Pluripotent Stem Cell (iPSC) Executive Summary
2. Table of Contents
3. List of Figures
4. List of Tables
5. Report Structure
6. Introduction6.1. Segmentation By Geography6.2. Segmentation By Derived Cell Type6.3. Segmentation By Application6.4. Segmentation By End-Use Industry
7. Induced Pluripotent Stem Cell (iPSC) Market Characteristics7.1. Segmentation By Derived Cell Type7.1.1. Hepatocytes7.1.2. Fibroblasts7.1.3. Keratinocytes7.1.4. Amniotic7.1.5. Others7.2. Segmentation By Application7.2.1. Academic Research7.2.2. Drug Discovery Toxicity Studies7.2.3. Regenerative Medicine7.2.4. Gene & Cell Therapy7.3. Segmentation By End-User7.3.1. Hospitals7.3.2. Research Laboratories
8. Induced Pluripotent Stem Cell (iPSC) Trends Strategies8.1. Use of Pluripotent Stem Cells in treating Parkinson's Disease (PD)8.2. Strategic Collaborations Partnerships8.3. Development Of Induced Pluripotent Stem Cell iPSC-Derived NK Cells8.4. Demand For Induced Pluripotent Stem Cell (iPSC) For Cell Therapy8.5. Expansion and Improvements in Drug Research8.6. Use of Pluripotent Stem Cells in treating Type 1 Diabetes
9. Impact Of Covid-19 On Induced Pluripotent Stem Cell (iPSC) Market9.1. Impact On Demand For Induced Pluripotent Stem Cells9.2. Increase In Research Development Activities
10. Global Induced Pluripotent Stem Cell (iPSC) Size Growth10.1. Market Size10.2. Historic Market Growth, 2015 - 2020, Value ($ Million)10.2.1. Drivers Of The Market 2015 - 202010.2.2. Restraints On The Market 2015 - 202010.3. Forecast Market Growth, 2020 - 2025, 2030F Value ($ Million)10.3.1. Drivers Of The Market 2020 - 202510.3.2. Restraints On The Market 2020 - 2025
11. Global Induced Pluripotent Stem Cell (iPSC) Segmentation11.1. Global Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Derived Cell Type , Historic Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)11.1.1. Fibroblasts11.1.2. Hepatocytes11.1.3. Keratinocytes11.1.4. Amniotic11.1.5. Others11.2. Global Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By Application, Historic Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)11.2.1. Drug Discovery & Toxicity Studies11.2.2. Academic Research11.2.3. Cell & Gene Therapy11.2.4. Regenerative Medicine11.3. Global Induced Pluripotent Stem Cell (iPSC) Market, Segmentation By End-Use Industry, Historic Forecast, 2015 - 2020, 2025F, 2030F, Value ($ Million)11.3.1. Research Laboratories11.3.2. Hospitals
Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/r/6e61hk
Media Contact:
Research and Markets Laura Wood, Senior Manager [emailprotected]
For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
http://www.researchandmarkets.com
The rest is here:
Global Induced Pluripotent Stem Cell (iPSC) Market Report 2021: Focus on Drug Discovery & Toxicity Studies, Academic Research, Cell & Gene...
- BENITEC BIOPHARMA INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com - February 13th, 2023 [February 13th, 2023]
- CENTOGENE to Participate in Upcoming Conferences in February in the Lead Up to Rare Disease Day - Marketscreener.com - February 7th, 2023 [February 7th, 2023]
- Gene | Definition, Structure, Expression, & Facts | Britannica - January 27th, 2023 [January 27th, 2023]
- New gene therapy delivers treatment directly to brain - January 27th, 2023 [January 27th, 2023]
- Indian Pharma Congress: Gene-cell therapy, preventive medicine future of health care, says expert - Economic Times - January 25th, 2023 [January 25th, 2023]
- A blood test that identifies people at higher risk of miscarriage? Thats the goal of this award-winning Rutgers med student. - The Philadelphia... - January 19th, 2023 [January 19th, 2023]
- Gene Therapy: Genes As Medicine | Pfizer - January 6th, 2023 [January 6th, 2023]
- How Genomics will ensure a risk-free and beneficial treatment for good health and well-being - The Financial Express - December 28th, 2022 [December 28th, 2022]
- Regenerative Medicine Advanced Therapy Designation | FDA - December 18th, 2022 [December 18th, 2022]
- 3576 - Gene ResultCXCL8 C-X-C motif chemokine ligand 8 [ (human)] - November 23rd, 2022 [November 23rd, 2022]
- Study identifies new gene that drives colon cancer - EurekAlert - October 17th, 2022 [October 17th, 2022]
- Updated Stroke Gene Panels: Rapid evolution of knowledge on monogenic causes of stroke | European Journal of Human Genetics - Nature.com - October 17th, 2022 [October 17th, 2022]
- The challenges of translating CRISPR to the clinic - Labiotech.eu - October 17th, 2022 [October 17th, 2022]
- Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene... - October 17th, 2022 [October 17th, 2022]
- 'We have to find a way': FDA seeks solutions to aid bespoke gene therapy - BioPharma Dive - October 17th, 2022 [October 17th, 2022]
- Mathematical model could bring us closer to effective stem cell therapies - Michigan Medicine - October 17th, 2022 [October 17th, 2022]
- Approval, Commercialization Highlighted at Cell & Gene Meeting on the Mesa - Genetic Engineering & Biotechnology News - October 17th, 2022 [October 17th, 2022]
- CANbridge-UMass Chan Medical School Gene Therapy Research in Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 29th Annual... - October 17th, 2022 [October 17th, 2022]
- Depression Treatment: How Genetic Testing Can Help Find the Right Medication - Dunya News - October 17th, 2022 [October 17th, 2022]
- The Risk-Reward Proposition for CGT Clinical Trials - Applied Clinical Trials Online - October 17th, 2022 [October 17th, 2022]
- Precision Medicine Could Get Even More Precise With Allarity Therapeutics Next-Generation Diagnostics - Benzinga - October 17th, 2022 [October 17th, 2022]
- Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals... - October 17th, 2022 [October 17th, 2022]
- Time for your medicine: unlocking the power of our body clocks - The Guardian - October 17th, 2022 [October 17th, 2022]
- Replay establishes distinguished Scientific Advisory Board of genomic medicine and cell therapy experts - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- Scientists Reappraise the Role of Zombie Cells That Anti-aging Medicine Has Sought to Eliminate - Neuroscience News - October 17th, 2022 [October 17th, 2022]
- Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe Disease - Business... - October 17th, 2022 [October 17th, 2022]
- Gene Expression Signatures Are Analyzed for Biomarkers of Response in HCC - Targeted Oncology - October 17th, 2022 [October 17th, 2022]
- NHS England World-first national genetic testing service to deliver rapid life-saving checks for babies and kids - NHS England - October 17th, 2022 [October 17th, 2022]
- The proteinprotein relationship that could mend a broken heart - RegMedNet - October 17th, 2022 [October 17th, 2022]
- Study finds microprotein correlated to Alzheimers risk - Daily Trojan Online - October 11th, 2022 [October 11th, 2022]
- Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer - Yahoo Finance - October 11th, 2022 [October 11th, 2022]
- Gene Therapy Rapidly Improves Night Vision in Adults with Congenital Blindness - Newswise - October 11th, 2022 [October 11th, 2022]
- Scientists Discover Protein Partners that Could Heal Heart Muscle | Newsroom - UNC Health and UNC School of Medicine - October 11th, 2022 [October 11th, 2022]
- The Pros and Cons of Lentiviral and Adeno-Associated Viral Vectors - The Medicine Maker - October 11th, 2022 [October 11th, 2022]
- Insights & Outcomes: Foreign DNA, quantum potholes and relapsing fever - Yale News - October 11th, 2022 [October 11th, 2022]
- Expediting IND applications with drug master files - BioPharma Dive - October 11th, 2022 [October 11th, 2022]
- UNC School of Medicine Awarded $3 Million to Lead Study to Reduce PTSD Frequency, Severity | Newsroom - UNC Health and UNC School of Medicine - October 11th, 2022 [October 11th, 2022]
- Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa - businesswire.com - October 8th, 2022 [October 8th, 2022]
- The Next Crispr Gene Editing IPO Could Be Near - Henry Herald - October 8th, 2022 [October 8th, 2022]
- 10-year CRISPR anniversary: How gene editing revolutionized medicine, and what lies ahead - Genetic Literacy Project - October 8th, 2022 [October 8th, 2022]
- Blood from a baby at birth can be gene sequenced to prevent diseases - USA TODAY - October 8th, 2022 [October 8th, 2022]
- What doctors wish patients knew about breast-cancer prevention - American Medical Association - October 8th, 2022 [October 8th, 2022]
- Growth in Cell and Gene Therapy Market - Pharmaceutical Technology Magazine - October 8th, 2022 [October 8th, 2022]
- Gene Editing Service Market 2022 : Top Players to Reflect Impressive Growth Rate till 2029: Caribou Biosciences, CRISPR Therapeutics, Merck KGaA,... - October 8th, 2022 [October 8th, 2022]
- Tip Sheet: $78 million to support new precision oncology institute, update on experimental gene therapy for herpes and the launch of Fred Hutch's new... - October 8th, 2022 [October 8th, 2022]
- Cell and Gene Therapy: Rewriting the Future of Medicine - Technology Networks - October 2nd, 2022 [October 2nd, 2022]
- Growth in Cell and Gene Therapy Market - BioPharm International - October 2nd, 2022 [October 2nd, 2022]
- CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130 for the Treatment of Cutaneous T-Cell... - October 2nd, 2022 [October 2nd, 2022]
- BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA - PR... - October 2nd, 2022 [October 2nd, 2022]
- Fighting Breast and Ovarian Cancer With a Lupus Antibody - Yale School of Medicine - October 2nd, 2022 [October 2nd, 2022]
- This gene therapy company is testing new tech to 'switch off' diabetes and obesity with a pill - Euronews - October 2nd, 2022 [October 2nd, 2022]
- Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Societys 2022 Scientific Sessions - Yahoo Finance - October 2nd, 2022 [October 2nd, 2022]
- Risk of Alzheimer's dementia may be predicted with help of new tool Washington University School of Medicine in St. Louis - Washington University... - October 2nd, 2022 [October 2nd, 2022]
- Tiny Sea Creature's Genes Shed Light on Evolution of Immunity - UPMC - October 2nd, 2022 [October 2nd, 2022]
- Who will get the call from Stockholm? It's time for STAT's 2022 Nobel Prize predictions - STAT - October 2nd, 2022 [October 2nd, 2022]
- Excision BioTherapeutics Awarded California Institute for Regenerative Medicine (CIRM) Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as... - October 2nd, 2022 [October 2nd, 2022]
- NeuroVoices: Emma Ciafaloni, MD, on the Vast Expansion of Innovative Approaches to Duchenne Muscular Dystrophy - Neurology Live - October 2nd, 2022 [October 2nd, 2022]
- COVID mRNA Jabs and Testing Kicked Off This Industry of Drug Development: Here's What You Need to Know - The Epoch Times - October 2nd, 2022 [October 2nd, 2022]
- Kidney resident macrophages have distinct subpopulations and occupy distinct microenvironments - University of Alabama at Birmingham - October 2nd, 2022 [October 2nd, 2022]
- Nobel Prize for medicine: the full list of winners - The National - October 2nd, 2022 [October 2nd, 2022]
- The surprising link between circadian disruption and cancer may have to do with temperature - EurekAlert - October 2nd, 2022 [October 2nd, 2022]
- The global live cell imaging market is expected to grow at a CAGR of 8.44% during 2022-2027 - Yahoo Finance - October 2nd, 2022 [October 2nd, 2022]
- Chroma Medicine Announces Formation of Scientific Advisory Board of Global Experts in Gene Editing and Cell and Gene Therapy - PR Newswire - September 20th, 2022 [September 20th, 2022]
- Ring Therapeutics Announces Issuance of U.S. Patent for its Anellovector Compositions - Yahoo Finance - September 20th, 2022 [September 20th, 2022]
- Cholesterol gene mutation: Why would a healthy 27-year-old have severe heart problems? - 69News WFMZ-TV - September 20th, 2022 [September 20th, 2022]
- Gene Therapy for Severe Hemophilia B Could Be More Cost Effective Than Current Treatments - Managed Healthcare Executive - September 20th, 2022 [September 20th, 2022]
- AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis... - September 20th, 2022 [September 20th, 2022]
- The Biggest CGT Breakthroughs Through the Eyes of Our 2022 Power List - The Medicine Maker - September 20th, 2022 [September 20th, 2022]
- Leading Virus Researcher to Chair UVA's Department of Microbiology, Immunology and Cancer Biology - UVA Health Newsroom - September 20th, 2022 [September 20th, 2022]
- Work remains on Tay-Sachs and other Ashkenazi genetic disorders J. - The Jewish News of Northern California - September 20th, 2022 [September 20th, 2022]
- Study Shows Genetic Link to Moving to the Beat of Music - Newswise - September 20th, 2022 [September 20th, 2022]
- Viewpoint: In the post Roe v Wade world, what changes should a biology textbook writer make to address the medical repercussions of Dobbs? - Genetic... - September 20th, 2022 [September 20th, 2022]
- Alnylam Receives Approval in Europe for AMVUTTRA (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult... - September 20th, 2022 [September 20th, 2022]
- CSL flexes gene therapy muscle with latest drug - Sydney Morning Herald - September 20th, 2022 [September 20th, 2022]
- The MIT Press releases new book on the science of the heart from cardiac expert Dr. Sian Harding - EurekAlert - September 20th, 2022 [September 20th, 2022]
- Global Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Reports Ltd - Yahoo... - September 20th, 2022 [September 20th, 2022]
- Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral ALZ-801... - September 20th, 2022 [September 20th, 2022]
- Do You Have Lung Cancer With An EGFR Mutation? If So, The Drug Tagrisso Might Be Right For You Based On New Results From A 'Practice Changing' Trial -... - September 20th, 2022 [September 20th, 2022]
- Getting rid of unwanted transformed cells: Possible new directions in cancer therapy - EurekAlert - September 20th, 2022 [September 20th, 2022]
- Sven Kili on reconvening with the ISCT - The Medicine Maker - September 14th, 2022 [September 14th, 2022]